{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:52:20Z","timestamp":1781761940670,"version":"3.54.5"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"IFPA"},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Almirall S.A."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13555-026-01814-x","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:46:03Z","timestamp":1780659963000},"page":"3687-3707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic Impact of Timely Systemic Treatment of Psoriatic Disease in Comorbidity Risk Reduction: Literature Review and (Early) Economic Assessment"],"prefix":"10.1007","volume":"16","author":[{"given":"Nicholas","family":"Norton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Nemeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Dhirta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk","family":"Geale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-1801","authenticated-orcid":false,"given":"Raquel","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"issue":"4","key":"1814_CR1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","volume":"74","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74(4):423\u201341.","journal-title":"Drugs"},{"issue":"23","key":"1814_CR2","doi-asserted-by":"publisher","first-page":"8359","DOI":"10.3390\/jcm14238359","volume":"14","author":"C Vergara-Dangond","year":"2025","unstructured":"Vergara-Dangond C, Cobo-Ib\u00e1\u00f1ez T, Cueva-N\u00e1jera G, Valverde-Garrido R, Garc\u00eda-Yubero C, Trives-Folguera L, et\u00a0al. Prevalence of psoriatic arthritis in patients with moderate-to-severe psoriasis in the era of biologics and small molecule therapies. J Clin Med. 2025;14(23):8359.","journal-title":"J Clin Med"},{"issue":"12","key":"1814_CR3","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1093\/rheumatology\/kead586","volume":"63","author":"KL Druce","year":"2024","unstructured":"Druce KL, Yimer BB, Humphreys J, Njuki LN, Bourke D, Li M, et\u00a0al. The epidemiology of psoriatic arthritis in the UK: a health intelligence analysis of UK primary care electronic health records 1991\u20132020. Rheumatology. 2024;63(12):3346\u201352.","journal-title":"Rheumatology"},{"issue":"9","key":"1814_CR4","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1136\/annrheumdis-2016-210963","volume":"76","author":"A Egeberg","year":"2017","unstructured":"Egeberg A, Kristensen LE, Thyssen JP, Gislason GH, Gottlieb AB, Coates LC, et\u00a0al. Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. Ann Rheum Dis. 2017;76(9):1591.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1814_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1684\/ejd.2022.4245","volume":"32","author":"Y Mou","year":"2022","unstructured":"Mou Y, Li F, Xu Y, Jin X, Dong S, Xia J. Global trends in the incidence of psoriasis from 1990 to 2019. Eur J Dermatol. 2022;32(2):207\u201313.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"1814_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000062","volume":"2","author":"EJ Armstrong","year":"2013","unstructured":"Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2(2):e000062.","journal-title":"J Am Heart Assoc"},{"issue":"14","key":"1814_CR7","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","volume":"296","author":"JM Gelfand","year":"2006","unstructured":"Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735\u201341.","journal-title":"JAMA"},{"issue":"6","key":"1814_CR8","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/jid.2013.508","volume":"134","author":"EA Dowlatshahi","year":"2014","unstructured":"Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol. 2014;134(6):1542\u201351.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1814_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jaad.2017.05.019","volume":"77","author":"S Singh","year":"2017","unstructured":"Singh S, Taylor C, Kornmehl H, Armstrong AW. Psoriasis and suicidality: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(3):425-40.e2.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1814_CR10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1001\/jamadermatol.2020.1398","volume":"156","author":"K Geale","year":"2020","unstructured":"Geale K, Henriksson M, Jokinen J, Schmitt-Egenolf M. Association of skin psoriasis and somatic comorbidity with the development of psychiatric illness in a Nationwide Swedish Study. JAMA Dermatol. 2020;156(7):795\u2013804.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1814_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/2013.jamadermatol.406","volume":"149","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(1):84\u201391.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1814_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2012.26","volume":"2","author":"AW Armstrong","year":"2012","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2(12):e54.","journal-title":"Nutr Diabetes"},{"issue":"4","key":"1814_CR13","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","volume":"80","author":"CA Elmets","year":"2019","unstructured":"Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, et\u00a0al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073\u2013113.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1814_CR14","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, et\u00a0al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1814_CR15","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","volume":"182","author":"NJ Korman","year":"2020","unstructured":"Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840\u20138.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1814_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.31138\/mjr.040123.sot","volume":"35","author":"E Pelechas","year":"2024","unstructured":"Pelechas E, Kaltsonoudis E, Migkos MP, Koletsos N, Karagianni PG, Drosos AA, et\u00a0al. State of the art review on the treatment of psoriatic disease. Mediterr J Rheumatol. 2024;35(1):66\u201372.","journal-title":"Mediterr J Rheumatol"},{"issue":"Suppl 2","key":"1814_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1468-3083.2011.04410.x","volume":"26","author":"K Reich","year":"2012","unstructured":"Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012;26(Suppl 2):3\u201311.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1814_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.03.1714","volume":"18","author":"S Feldman","year":"2015","unstructured":"Feldman S, Princic N, Zhao Y, Barghout V, Willson T, Song X, et\u00a0al. Mortality risk in patients with psoriasis. Value Health. 2015;18(3):A294.","journal-title":"Value Health"},{"issue":"12","key":"1814_CR19","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1001\/archderm.143.12.1493","volume":"143","author":"JM Gelfand","year":"2007","unstructured":"Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et\u00a0al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143(12):1493\u20139.","journal-title":"Arch Dermatol"},{"key":"1814_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1407454","volume":"11","author":"Z Wei","year":"2024","unstructured":"Wei Z, Nie G, Sadik CD, Shan D. Associations between body mass index and all-cause mortality among individuals with psoriasis: results from the NHANES database retrospective cohort study. Front Nutr. 2024;11:1407454.","journal-title":"Front Nutr"},{"issue":"4","key":"1814_CR21","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/ced\/llae449","volume":"50","author":"K Williams","year":"2025","unstructured":"Williams K, Lada G, Reynolds NJ, McElhone K, Evans I, Warren RB, et\u00a0al. Risk of suicide and suicidality in patients with moderate to severe psoriasis: results from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Clin Exp Dermatol. 2025;50(4):804\u201311.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"1814_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s13671-013-0066-6","volume":"3","author":"R Gupta","year":"2014","unstructured":"Gupta R, Debbaneh MG, Liao W. Genetic epidemiology of psoriasis. Curr Dermatol Rep. 2014;3(1):61\u201378.","journal-title":"Curr Dermatol Rep"},{"issue":"1","key":"1814_CR23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s12913-017-2278-0","volume":"17","author":"SR Feldman","year":"2017","unstructured":"Feldman SR, Tian H, Gilloteau I, Mollon P, Shu M. Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database. BMC Health Serv Res. 2017;17(1):337.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"1814_CR24","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s13555-022-00832-9","volume":"13","author":"JJ Wu","year":"2023","unstructured":"Wu JJ, Suryavanshi M, Davidson D, Patel V, Jain A, Seigel L. Economic burden of comorbidities in patients with psoriasis in the USA. Dermatol Ther (Heidelb). 2023;13(1):207\u201319.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1814_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00117","volume":"11","author":"P Gisondi","year":"2020","unstructured":"Gisondi P, Bellinato F, Girolomoni G, Albanesi C. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front Pharmacol. 2020;11:117.","journal-title":"Front Pharmacol"},{"key":"1814_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169063","author":"S Piaserico","year":"2022","unstructured":"Piaserico S, Orlando G, Messina F. Psoriasis and cardiometabolic diseases: shared genetic and molecular pathways. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23169063.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1814_CR27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","volume":"8","author":"J Guo","year":"2023","unstructured":"Guo J, Zhang H, Lin W, Lu L, Su J, Chen X. Signaling pathways and targeted therapies for psoriasis. Signal Transduct Target Ther. 2023;8(1):437.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"1814_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/1744666X.2022.2008240","volume":"18","author":"A Abduelmula","year":"2022","unstructured":"Abduelmula A, Gooderham MJ. TYK2 inhibition: changing the treatment landscape for psoriasis? Expert Rev Clin Immunol. 2022;18(3):185\u20137.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"1814_CR29","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.immuni.2023.04.001","volume":"56","author":"R Bharadwaj","year":"2023","unstructured":"Bharadwaj R, Lusi CF, Mashayekh S, Nagar A, Subbarao M, Kane GI, et\u00a0al. Methotrexate suppresses psoriatic skin inflammation by inhibiting muropeptide transporter SLC46A2 activity. Immunity. 2023;56(5):998-1012.e8.","journal-title":"Immunity"},{"issue":"9","key":"1814_CR30","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","volume":"108","author":"R Micha","year":"2011","unstructured":"Micha R, Imamura F, von WylerBallmoos M, Solomon DH, Hern\u00e1n MA, Ridker PM, et\u00a0al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108(9):1362\u201370.","journal-title":"Am J Cardiol"},{"issue":"1","key":"1814_CR31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","volume":"81","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Bellinato F, Targher G, Idolazzi L, Girolomoni G. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68\u201373.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1814_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004591","volume":"22","author":"TL Lin","year":"2025","unstructured":"Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-\u03b1, IL-12\/23, IL-17, and IL-23: a population-based retrospective cohort study. PLoS Med. 2025;22(4):e1004591.","journal-title":"PLoS Med"},{"issue":"1","key":"1814_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jaad.2025.03.055","volume":"93","author":"WJ Song","year":"2025","unstructured":"Song WJ, Oh S, Yoon HS. Association between biologic and nonbiologic systemic therapy for psoriasis and psoriatic arthritis and the risk of new-onset and recurrent major adverse cardiovascular events: a retrospective cohort study. J Am Acad Dermatol. 2025;93(1):141\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1814_CR34","doi-asserted-by":"publisher","first-page":"621","DOI":"10.36849\/JDD.7119","volume":"22","author":"E Darwin","year":"2023","unstructured":"Darwin E, Lebwohl M, Han G. Biologic Vs conventional therapies: comparing risk of psoriasis-associated comorbidities. J Drugs Dermatol. 2023;22(6):621\u20132.","journal-title":"J Drugs Dermatol"},{"issue":"22","key":"1814_CR35","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003816","volume":"95","author":"CY Wu","year":"2016","unstructured":"Wu CY, Chang YT, Juan CK, Shen JL, Lin YP, Shieh JJ, et\u00a0al. Depression and insomnia in patients with psoriasis and psoriatic arthritis taking tumor necrosis factor antagonists. Medicine (Baltimore). 2016;95(22):e3816.","journal-title":"Medicine (Baltimore)"},{"key":"1814_CR36","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jdin.2024.02.016","volume":"16","author":"C Cavanaugh","year":"2024","unstructured":"Cavanaugh C, Orroth K, Qian X, Kumparatana P, Klyachkin Y, Colgan S, et\u00a0al. Diabetes and obesity burden and improvements in cardiometabolic parameters in patients with psoriasis or psoriatic arthritis receiving apremilast in a real-world setting. JAAD Int. 2024;16:244\u201351.","journal-title":"JAAD Int"},{"issue":"11","key":"1814_CR37","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/jdv.12024","volume":"27","author":"E Daud\u00e9n","year":"2013","unstructured":"Daud\u00e9n E, Casta\u00f1eda S, Su\u00e1rez C, Garc\u00eda-Campayo J, Blasco AJ, Aguilar MD, et\u00a0al. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J Eur Acad Dermatol Venereol. 2013;27(11):1387\u2013404.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1814_CR38","volume":"16","author":"E Mortato","year":"2024","unstructured":"Mortato E, Baratta S, Rubino L, De Caro AP, Loconsole F. Cost analysis in the management of moderate-to-severe psoriasis: comparison between conventional and biological systemic therapies. Dermatol Rep. 2024;16(1):9755.","journal-title":"Dermatol Rep"},{"key":"1814_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-35","volume":"4","author":"MJ Bhosle","year":"2006","unstructured":"Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4:35.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"1814_CR40","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.amjopharm.2007.05.004","volume":"5","author":"MJ Bhosle","year":"2007","unstructured":"Bhosle MJ, Reardon G, Camacho FT, Anderson RT, Balkrishnan R. Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a Medicare managed care population. Am J Geriatr Pharmacother. 2007;5(2):100\u201311.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"4","key":"1814_CR41","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/j.1365-2133.2010.09944.x","volume":"163","author":"A Fonia","year":"2010","unstructured":"Fonia A, Jackson K, Lereun C, Grant DM, Barker JN, Smith CH. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol. 2010;163(4):807\u201316.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1814_CR42","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2340\/00015555-2329","volume":"96","author":"A Svedbom","year":"2016","unstructured":"Svedbom A, Dahl\u00e9n J, Mamolo C, Cappelleri JC, Mallbris L, Petersson IF, et\u00a0al. Economic burden of psoriasis and potential cost offsets with biologic treatment: a Swedish register analysis. Acta Derm Venereol. 2016;96(5):651\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1814_CR43","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et\u00a0al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Sect. 1 Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826\u201350.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1814_CR44","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1177\/1203475416658004","volume":"20","author":"WP Gulliver","year":"2016","unstructured":"Gulliver WP, Young HM, Bachelez H, Randell S, Gulliver S, Al-Mutairi N. Psoriasis patients treated with biologics and methotrexate have a reduced rate of myocardial infarction: a collaborative analysis using international cohorts. J Cutan Med Surg. 2016;20(6):550\u20134.","journal-title":"J Cutan Med Surg"},{"issue":"12","key":"1814_CR45","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1007\/s13555-023-01062-3","volume":"13","author":"HT Nguyen","year":"2023","unstructured":"Nguyen HT, Vu AT, Pham NTU, Tran TNA, Pham NN, Bui HTT, et\u00a0al. Comorbidity burden and treatment patterns of psoriasis in Vietnam: real-world data from the EXPAND Study. Dermatol Ther (Heidelb). 2023;13(12):3193\u2013208.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1814_CR46","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1159\/000499924","volume":"235","author":"SF Thomsen","year":"2019","unstructured":"Thomsen SF, Skov L, Dodge R, Hedegaard MS, Kjellberg J. Socioeconomic costs and health inequalities from psoriasis: a cohort study. Dermatology. 2019;235(5):372\u20139.","journal-title":"Dermatology"},{"key":"1814_CR47","unstructured":"Kaiser Family Foundation (KFF). Key Facts about the Uninsured Population USA: KFF; 2024 [Available from: https:\/\/www.kff.org\/uninsured\/key-facts-about-the-uninsured-population\/."},{"key":"1814_CR48","unstructured":"Commonwealth Fund. U.S. Health Insurance Coverage in 2020: A Looming Crisis in Affordability USA: Commonwealth Fund; 2020 [Available from: https:\/\/www.commonwealthfund.org\/publications\/issue-briefs\/2020\/aug\/looming-crisis-health-coverage-2020-biennial."},{"issue":"5","key":"1814_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0304821","volume":"19","author":"DH Thi Bui","year":"2024","unstructured":"Thi Bui DH, Nguyen BX, S\u00f8ndergaard J, Gammeltoft TM, Bygbjerg IC, Nielsen J, et\u00a0al. Informal caregiving among people supporting a person with type 2 diabetes in rural communities of Northern Vietnam: a cross-sectional study of caregiver burdens. PLoS ONE. 2024;19(5):e0304821.","journal-title":"PLoS ONE"},{"issue":"3","key":"1814_CR50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/13648470.2021.1994334","volume":"29","author":"TM Gammeltoft","year":"2022","unstructured":"Gammeltoft TM, Huy\u1ec1n Di\u1ec7u BT, Kim Dung VT, \u0110\u1ee9c Anh V, Minh Hi\u1ebfu L, Th\u1ecb \u00c1N. Existential vulnerability: an ethnographic study of everyday lives with diabetes in Vietnam. Anthropol Med. 2022;29(3):271\u201388.","journal-title":"Anthropol Med"},{"key":"1814_CR51","unstructured":"Augustin M, Griffiths C, Romiti R, Guevara-Sangines E, Jo S-J, Howe T, et\u00a0al. Systemic eligible psoriasis patients with comorbidities experience worse disease burden: Results from a large observational physician and patient survey. 2017."},{"issue":"6","key":"1814_CR52","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s00296-022-05126-z","volume":"42","author":"K Klavdianou","year":"2022","unstructured":"Klavdianou K, Stavropoulou M, Panagakis P, Papoutsaki M, Panagiotopoulos A, Koutsianas C, et\u00a0al. Patient characteristics, treatment patterns and disease outcomes in patients with psoriatic arthritis followed in a combined dermatology-rheumatology clinic: a retrospective real-world study. Rheumatol Int. 2022;42(6):1035\u201341.","journal-title":"Rheumatol Int"},{"issue":"5","key":"1814_CR53","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3899\/jrheum.170148","volume":"44","author":"JP Okhovat","year":"2017","unstructured":"Okhovat JP, Ogdie A, Reddy SM, Rosen CF, Scher JU, Merola JF. Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) survey: benefits and challenges of combined rheumatology-dermatology clinics. J Rheumatol. 2017;44(5):693\u20134.","journal-title":"J Rheumatol"},{"issue":"3","key":"1814_CR54","doi-asserted-by":"publisher","first-page":"506","DOI":"10.31138\/mjr.051223.cop","volume":"35","author":"E Sotiriou","year":"2024","unstructured":"Sotiriou E, Bakirtzi K, Papadimitriou I, Paschou E, Kiritsi D, Kougkas N, et\u00a0al. Clinical outcomes and patients\u2019 perspectives of multidisciplinary psoriasis management: a five-year retrospective study. Mediterr J Rheumatol. 2024;35(3):506\u20139.","journal-title":"Mediterr J Rheumatol"},{"issue":"4","key":"1814_CR55","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jaad.2011.02.022","volume":"66","author":"K Parsi","year":"2012","unstructured":"Parsi K, Chambers CJ, Armstrong AW. Cost-effectiveness analysis of a patient-centered care model for management of psoriasis. J Am Acad Dermatol. 2012;66(4):563\u201370.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1814_CR56","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s40273-024-01428-1","volume":"42","author":"IC Antonazzo","year":"2024","unstructured":"Antonazzo IC, Gribaudo G, La Vecchia A, Ferrara P, Piraino A, Cortesi PA, et\u00a0al. Cost and cost effectiveness of treatments for psoriatic arthritis: an updated systematic literature review. Pharmacoeconomics. 2024;42(12):1329\u201343.","journal-title":"Pharmacoeconomics"},{"key":"1814_CR57","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/j.jval.2019.04.104","volume":"22","author":"G Barbado","year":"2019","unstructured":"Barbado G, Waker M, Levysohn A, Bodin M, Keady S. PBI21 evaluation of the cost saving potential of introducing an Adalimumab biosimilar for the treatment of all licensed adult adalimumab indications in Spain. Value in Health. 2019;22:S50.","journal-title":"Value in Health"},{"issue":"11","key":"1814_CR58","first-page":"1226","volume":"30","author":"S Chaplin","year":"2024","unstructured":"Chaplin S, van Stiphout J, Chen A, Li E. Budget impact analysis of including biosimilar adalimumab on formulary: a United States payer perspective. J Manag Care Spec Pharm. 2024;30(11):1226\u201338.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"1814_CR59","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jamadermatol.2023.6236","volume":"160","author":"AC Egilman","year":"2024","unstructured":"Egilman AC, Kesselheim AS, Avorn J, Raymakers AJN, Rome BN. Use of efficiency frontiers to align prices and clinical benefits of biologic therapies for plaque psoriasis. JAMA Dermatol. 2024;160(4):409\u201316.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"1814_CR60","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/ard-2022-223696","volume":"82","author":"M Stajszczyk","year":"2023","unstructured":"Stajszczyk M, Obarska I, Jeka S, Batko B. Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database. Ann Rheum Dis. 2023;82(9):1171\u201380.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1814_CR61","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028732","volume":"12","author":"A Malhotra","year":"2023","unstructured":"Malhotra A, Cole KV, Malik AS, P\u00e9pin JL, Sert Kuniyoshi FH, Cistulli PA, et\u00a0al. Positive airway pressure adherence and health care resource utilization in patients with obstructive sleep apnea and heart failure with reduced ejection fraction. J Am Heart Assoc. 2023;12(10):e028732.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"1814_CR62","first-page":"95","volume":"14","author":"J Unutzer","year":"2008","unstructured":"Unutzer J, Katon WJ, Fan MY, Schoenbaum MC, Lin EH, Della Penna RD, et\u00a0al. Long-term cost effects of collaborative care for late-life depression. Am J Manag Care. 2008;14(2):95\u2013100.","journal-title":"Am J Manag Care"},{"issue":"9","key":"1814_CR63","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.2337\/dc25-0254","volume":"48","author":"CE Sloan","year":"2025","unstructured":"Sloan CE, Zepel L, Smith VA, Arterburn DE, Baecker A, Clark AG, et\u00a0al. Health expenditures decline after bariatric surgery for patients with Type 2 diabetes. Diabetes Care. 2025;48(9):1502\u201311.","journal-title":"Diabetes Care"},{"key":"1814_CR64","unstructured":"Global Psoriasis Atlas (GPA). Prevalence Heat Map: GPA; 2025 [Available from: https:\/\/www.globalpsoriasisatlas.org\/en\/explore\/prevalence-heatmap."},{"issue":"8","key":"1814_CR65","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","volume":"157","author":"AW Armstrong","year":"2021","unstructured":"Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940\u20136.","journal-title":"JAMA Dermatol"},{"key":"1814_CR66","unstructured":"National Psoriasis Foundation (NPF). NPF home page USA2025 [Available from: https:\/\/www.psoriasis.org\/."},{"issue":"3","key":"1814_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265741","volume":"17","author":"J Augustin","year":"2022","unstructured":"Augustin J, Wolf S, Stephan B, Augustin M, Andrees V. Psoriasis comorbidities in Germany: a population-based study on spatiotemporal variations. PLoS ONE. 2022;17(3):e0265741.","journal-title":"PLoS ONE"},{"key":"1814_CR68","unstructured":"United Nations. UN Population Division Data Portal - Interactive access to global demographic indicators Belgium: UN; 2024 [Available from: https:\/\/population.un.org\/dataportal\/home?df=79bab212-b904-44dc-95be-983b707034e3."},{"issue":"2","key":"1814_CR69","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/13696998.2018.1557201","volume":"22","author":"D Pilon","year":"2019","unstructured":"Pilon D, Teeple A, Zhdanava M, Ladouceur M, Ching Cheung H, Muser E, et\u00a0al. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. J Med Econ. 2019;22(2):196\u2013203.","journal-title":"J Med Econ"},{"issue":"7","key":"1814_CR70","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3899\/jrheum.180670","volume":"46","author":"HG Tekin","year":"2019","unstructured":"Tekin HG, Wu JJ, Burge R, Birt J, Egeberg A. Burden and disease characteristics of patients with psoriatic arthritis: a population-based cross-sectional study. J Rheumatol. 2019;46(7):716\u201320.","journal-title":"J Rheumatol"},{"issue":"4","key":"1814_CR71","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s40744-021-00370-4","volume":"8","author":"A Ogdie","year":"2021","unstructured":"Ogdie A, Matthias W, Thielen RJ, Chin D, Saffore CD. Racial differences in prevalence and treatment for psoriatic arthritis and ankylosing spondylitis by insurance coverage in the USA. Rheumatol Ther. 2021;8(4):1725\u201339.","journal-title":"Rheumatol Ther"},{"issue":"10","key":"1814_CR72","first-page":"2252","volume":"30","author":"MH Tt","year":"2003","unstructured":"Tt MH, Darmawan J, Chen SL, N VH, C TN, T NA. Prevalence of the rheumatic diseases in urban Vietnam: a WHO-ILAR COPCORD study. J Rheumatol. 2003;30(10):2252\u20136.","journal-title":"J Rheumatol"},{"issue":"2","key":"1814_CR73","first-page":"187","volume":"17","author":"AS Paller","year":"2018","unstructured":"Paller AS, Singh R, Cloutier M, Gauthier-Loiselle M, Emond B, Gu\u00e9rin A, et\u00a0al. Prevalence of psoriasis in children and adolescents in the United States: a claims-based analysis. J Drugs Dermatol. 2018;17(2):187\u201394.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"1814_CR74","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-028116","volume":"9","author":"A Egeberg","year":"2019","unstructured":"Egeberg A, Andersen YMF, Thyssen JP. Prevalence and characteristics of psoriasis in Denmark: findings from the Danish skin cohort. BMJ Open. 2019;9(3):e028116.","journal-title":"BMJ Open"},{"issue":"6","key":"1814_CR75","doi-asserted-by":"publisher","first-page":"761","DOI":"10.5021\/ad.2017.29.6.761","volume":"29","author":"JY Lee","year":"2017","unstructured":"Lee JY, Kang S, Park JS, Jo SJ. Prevalence of psoriasis in Korea: a population-based epidemiological study using the Korean National Health Insurance Database. Ann Dermatol. 2017;29(6):761\u20137.","journal-title":"Ann Dermatol"},{"issue":"23","key":"1814_CR76","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/j.jacc.2025.03.546","volume":"85","author":"KF Faridi","year":"2025","unstructured":"Faridi KF, Malik D, Essa M, Yang H, Spatz ES, Krumholz HM, et\u00a0al. 10-Year and 30-year risks of cardiovascular disease in the US population. J Am Coll Cardiol. 2025;85(23):2239\u201349.","journal-title":"J Am Coll Cardiol"},{"key":"1814_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.829709","volume":"9","author":"L Liu","year":"2022","unstructured":"Liu L, Cui S, Liu M, Huo X, Zhang G, Wang N. Psoriasis increased the risk of adverse cardiovascular outcomes: a new systematic review and meta-analysis of cohort study. Front Cardiovasc Med. 2022;9:829709.","journal-title":"Front Cardiovasc Med"},{"key":"1814_CR78","unstructured":"Hjerteforeningen (Danish Heart Association). Heart Numbers: Cardiovascular diseases: total cases (18+ years old) 2023 2023 [Available from: https:\/\/hjerteforeningen.shinyapps.io\/HjerteTal\/?_inputs_&agCVD=%22national%22&bar=%22cvd%22&oCVD=%22d1%22&varCVD=%22v2%22&year=%222023%22."},{"key":"1814_CR79","unstructured":"Statistics Denmark (DST). Statistics denmark: Population figures Denmark: DST; 2025 [Available from: https:\/\/www.dst.dk\/en\/Statistik\/emner\/borgere\/befolkning\/befolkningstal."},{"key":"1814_CR80","volume-title":"National survey on the risk factors of noncommunicable diseases in Viet Nam, 2021","author":"World Health Organization (WHO)","year":"2021","unstructured":"World Health Organization (WHO). National survey on the risk factors of noncommunicable diseases in Viet Nam, 2021. WHO; 2021."},{"issue":"1","key":"1814_CR81","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/bjd.16332","volume":"179","author":"CEM Griffiths","year":"2018","unstructured":"Griffiths CEM, Jo SJ, Naldi L, Romiti R, Guevara-Sangines E, Howe T, et\u00a0al. A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. Br J Dermatol. 2018;179(1):173\u201381.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1814_CR82","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/03007995.2022.2129803","volume":"39","author":"X Sun","year":"2023","unstructured":"Sun X, Zhao H, Wang R, Li H, Wu Y, Ze K, et\u00a0al. Psoriasis complicated with metabolic disorder is associated with traditional Chinese medicine syndrome types: a hospital-based retrospective case-control study. Curr Med Res Opin. 2023;39(1):19\u201325.","journal-title":"Curr Med Res Opin"},{"key":"1814_CR83","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003412","author":"SB Vestergaard","year":"2024","unstructured":"Vestergaard SB, Esbensen BA, Klausen JM, Glintborg B, Lau L, Yilmaz Jantzen C, et\u00a0al. Prevalence of anxiety and depression and the association with self-management behaviour in >12 000 patients with inflammatory rheumatic disease: a cross-sectional nationwide study. RMD Open. 2024. https:\/\/doi.org\/10.1136\/rmdopen-2023-003412.","journal-title":"RMD Open"},{"issue":"3","key":"1814_CR84","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/13548506.2018.1529323","volume":"24","author":"Z Tian","year":"2019","unstructured":"Tian Z, Huang Y, Yue T, Zhou J, Tao L, Han L, et\u00a0al. A Chinese cross-sectional study on depression and anxiety symptoms in patients with psoriasis vulgaris. Psychol Health Med. 2019;24(3):269\u201380.","journal-title":"Psychol Health Med"},{"issue":"10","key":"1814_CR85","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1093\/rheumatology\/keae080","volume":"63","author":"H Gouze","year":"2024","unstructured":"Gouze H, Aegerter P, Gouyette Y, Breban M, D\u2019Agostino MA. Risk of cardiovascular disease decreases over time in psoriatic arthritis but not in spondylarthritis: meta-analysis of longitudinal studies. Rheumatology (Oxford). 2024;63(10):2638\u201347.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"1814_CR86","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/acr.23171","volume":"69","author":"H Radner","year":"2017","unstructured":"Radner H, Lesperance T, Accortt NA, Solomon DH. Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis. Arthritis Care Res (Hoboken). 2017;69(10):1510\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"1814_CR87","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/rheumatology\/ket343","volume":"53","author":"M Dubreuil","year":"2014","unstructured":"Dubreuil M, Rho YH, Man A, Zhu Y, Zhang Y, Love TJ, et\u00a0al. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology (Oxford). 2014;53(2):346\u201352.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1814_CR88","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jaclp.2021.12.007","volume":"63","author":"G Lada","year":"2022","unstructured":"Lada G, Chinoy H, Heal C, Warren RB, Talbot PS, Kleyn CE. Depression and suicidality in patients with psoriasis and the role of psoriatic arthritis: a cross-sectional study in a tertiary setting. J Acad Consult Liaison Psychiatry. 2022;63(4):372\u201383.","journal-title":"J Acad Consult Liaison Psychiatry"},{"issue":"10","key":"1814_CR89","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1007\/s10067-021-05713-8","volume":"40","author":"JF Merola","year":"2021","unstructured":"Merola JF, Dennis N, Chakravarty SD, Villacorta R, Mesana L, Lin I, et\u00a0al. Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 to 2020. Clin Rheumatol. 2021;40(10):4061\u201370.","journal-title":"Clin Rheumatol"},{"issue":"9","key":"1814_CR90","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1136\/annrheumdis-2016-210579","volume":"76","author":"LE Kristensen","year":"2017","unstructured":"Kristensen LE, Jorgensen TS, Christensen R, Gudbergsen H, Dreyer L, Ballegaard C, et\u00a0al. Societal costs and patients\u2019 experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study. Ann Rheum Dis. 2017;76(9):1495\u2013501.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1814_CR91","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2213-8587(18)30288-2","volume":"6","author":"K Bhaskaran","year":"2018","unstructured":"Bhaskaran K, Dos-Santos-Silva I, Leon DA, Douglas IJ, Smeeth L. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults in the UK. Lancet Diabetes Endocrinol. 2018;6(12):944\u201353.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"1814_CR92","doi-asserted-by":"publisher","first-page":"667","DOI":"10.7326\/0003-4819-159-10-201311190-00005","volume":"159","author":"H Cho","year":"2013","unstructured":"Cho H, Klabunde CN, Yabroff KR, Wang Z, Meekins A, Lansdorp-Vogelaar I, et\u00a0al. Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies. Ann Intern Med. 2013;159(10):667\u201376.","journal-title":"Ann Intern Med"},{"key":"1814_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euroneuro.2024.10.009","volume":"91","author":"HKY Lo","year":"2025","unstructured":"Lo HKY, Chan JKN, Wong CSM, Chung KF, Correll CU, Solmi M, et\u00a0al. Excess mortality and life-years lost in people diagnosed with depression: a 20-year population-based cohort study of 126,573 depressed individuals followed for 1,139,073 persons-years. Eur Neuropsychopharmacol. 2025;91:1\u20138.","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01814-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01814-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01814-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:03:09Z","timestamp":1781758989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01814-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":93,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1814"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01814-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nicholas Norton, Zoltan Nemeth, Soumya Nanda, Abhishek Dhirta and Kirk Geale are all employees of Quantify Research, an HEOR consultancy, which received funding from IFPA to conduct this study. Raquel Vaz is the scientific project lead of IFPA, which commissioned the project. Raquel Vaz has been a speaker at events hosted by Boehringer Ingelheim and Takeda Pharmaceuticals; consultant for Takeda Pharmaceuticals and Johnson and Johnson; and research grant holder from Takeda Pharmaceuticals. The authors declare no other conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study did not involve human participants or animals and was based exclusively on data from previously published sources. Therefore, ethical approval and informed consent were not required. The research and reporting were conducted in accordance with the principles outlined in the International Committee of Medical Journal Editors (ICMJE) recommendations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}